NSE filing, NSE: EMCURE. Summary written from the filing by ALFA Finder's alert engine.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,883.50
- Market cap
- ₹35,732 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 35.3×Sector 47.2×
- Promoter holding
- 77.82%-0.01% QoQ
- FII holding
- 4.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.
Emcure Pharmaceuticals Board Meeting Date
Emcure Pharmaceuticals will hold a board meeting on November 03, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.
Emcure Pharmaceuticals Acquisition
Emcure Pharmaceuticals approved the merger of its wholly-owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. The internal restructuring involves no cash consideration or share issuance.
Emcure Pharmaceuticals Legal & Regulatory
Emcure Pharmaceuticals received Income-tax Department orders imposing aggregate penalties of Rs. 57.74 Crore for assessment years 2015-16 to 2021-22. The company is evaluating legal remedies.
- Value
- ₹57.74 Cr
Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Other credit rating announcements
All →Tiger Logistics (India) Credit Rating
Tiger Logistics disclosed that Infomerics reaffirmed its credit ratings at IVR A-/Negative long-term and IVR A2+ short-term. The press release also reports Q2 revenue of ₹225.14 crore and H1 revenue of ₹377.66 crore.
Ambani Orgochem Credit Rating
Infomerics upgraded Ambani Orgochem's bank loan ratings to IVR BBB-/Stable and removed them from Issuer Not Cooperating. The action reflects improved financial risk profile.
Popular Vehicles and Services Credit Rating
Popular Vehicles and Services reported that CRISIL reaffirmed its wholly owned subsidiary's rating at CRISIL A/Stable and CRISIL A1. The reaffirmation is valid until 31 March 2027.
Vishnu Chemicals Credit Rating
ICRA assigned Vishnu Chemicals an A (Stable) long-term credit rating on banking facilities. The rating covers total limits of ₹630 Crore, up from the prior CARE A- rating.
Brahmaputra Infrastructure Credit Rating
CARE Ratings upgraded Brahmaputra Infrastructure's bank facility ratings from BBB- to BBB with Stable outlook. The upgrade covers ₹229.84 Crore in long-term and short-term bank facilities.
Texmaco Rail & Engineering Credit Rating
Crisil Ratings assigned Texmaco Rail & Engineering a long-term bank facilities rating of Crisil A+/Stable. The rating is disclosed under Regulation 30.